Johnson & Johnson has agreed to settle a large chunk of lawsuits over its diabetes drug Invokana.

In an Oct. 16 motion, Michael London, of New York-based Douglas & London, who is co-lead plaintiffs’ counsel in the multidistrict litigation in New Jersey, asked the court to set up a qualified settlement fund of a “confidential settlement amount” to resolve his inventory of cases.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]